Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 11/20 | 0.52 |
| ▸ | XPO1 | O14980 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899214 | 1.00 | PTGES (0.52) | PTGESXPO1KDM4EHPGDDRD2 | |
| SCHEMBL19064507 | 0.90 | P2RX1 (0.55) | PTGESTMPRSS4 | |
| SCHEMBL29577337 | 0.90 | P2RX1 (0.55) | PTGESTMPRSS4 | |
| SCHEMBL21645628 | 0.86 | PTGES (0.54) | PTGESKDM4ETMPRSS4 | |
| SCHEMBL30899219 | 0.86 | PTGES (0.54) | PTGESKDM4ETMPRSS4 | |
| SCHEMBL21645373 | 0.85 | MAPT (0.47) | PTGES | |
| SCHEMBL30899218 | 0.85 | MAPT (0.47) | PTGES | |
| SCHEMBL21645367 | 0.82 | PTGES (0.52) | PTGES | |
| SCHEMBL19064517 | 0.81 | KDM4E (0.61) | KDM4EHPGDDRD2DRD4DRD3 | |
| SCHEMBL2370001 | 0.77 | PARP1 (0.62) | KDM4EHPGDDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DUKE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| WO-2020028392-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DNER, SFRP1, WNT1 | PTGES 1773/4885XPO1 4272/4885KDM4E 1047/4885 |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DNER, SFRP1, WNT1 | PTGES 1773/4885XPO1 4272/4885KDM4E 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.